G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:GTHX
- CUSIP: N/A
- Web: www.g1therapeutics.com
Capitalization:- Market Cap: $699.49 million
- Outstanding Shares: 28,285,000
Average Prices:- 50 Day Moving Avg: $18.63
- 200 Day Moving Avg: $17.51
- 52 Week Range: $12.04 - $28.67
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.66
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $4.37 per share
- Price / Book: 5.66
Profitability:Debt:- Current Ratio: 12.85%
- Quick Ratio: 12.85%
Misc:- Average Volume: 80,419 shs.
- Short Ratio: 10.41
Frequently Asked Questions for G1 THERAPEUTICS (NASDAQ:GTHX)
What is G1 THERAPEUTICS's stock symbol?
G1 THERAPEUTICS trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 THERAPEUTICS's earnings last quarter?
G1 THERAPEUTICS (NASDAQ:GTHX) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.48. View G1 THERAPEUTICS's Earnings History.
When will G1 THERAPEUTICS make its next earnings announcement?
Where is G1 THERAPEUTICS's stock going? Where will G1 THERAPEUTICS's stock price be in 2017?
4 analysts have issued 1-year price targets for G1 THERAPEUTICS's stock. Their predictions range from $23.00 to $34.00. On average, they expect G1 THERAPEUTICS's stock price to reach $29.75 in the next twelve months. View Analyst Ratings for G1 THERAPEUTICS.
Who are some of G1 THERAPEUTICS's key competitors?
Some companies that are related to G1 THERAPEUTICS include Lexicon Pharmaceuticals (LXRX), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Xencor (XNCR), NeuroDerm (NDRM), Omeros Corporation (OMER), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Amarin Corporation PLC (AMRN), Retrophin (RTRX), ZIOPHARM Oncology (ZIOP), REGENXBIO (RGNX) and Intra-Cellular Therapies (ITCI).
Who are G1 THERAPEUTICS's key executives?
G1 THERAPEUTICS's management team includes the folowing people:
- Seth A. Rudnick M.D., Chairman of the Board
- Mark A. Velleca Ph.D., M.D., President, Chief Executive Officer, Director
- Jay C. Strum Ph.D., Chief Scientific Officer
- Jennifer K. Moses, Vice President - Finance and Administration
- Rajesh K. Malik M.D., Chief Medical Officer
- Gregory J. Mossinghoff, Chief Business Officer, Secretary
- Andrew Philip Witty, Director
- Fredric N. Eshelman Pharm.D., Independent Director
- Glenn P. Muir, Independent Director
- Tyrell J. Rivers, Independent Director
When did G1 THERAPEUTICS IPO?
(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who owns G1 THERAPEUTICS stock?
G1 THERAPEUTICS's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (181.37%), FMR LLC (132.09%), Franklin Resources Inc. (41.26%), Hillhouse Capital Management Ltd. (30.41%), Laurion Capital Management LP (13.51%) and Chartwell Investment Partners LLC (5.96%). Company insiders that own G1 THERAPEUTICS stock include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for G1 THERAPEUTICS.
Who bought G1 THERAPEUTICS stock? Who is buying G1 THERAPEUTICS stock?
G1 THERAPEUTICS's stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, Franklin Resources Inc., Hillhouse Capital Management Ltd., Laurion Capital Management LP, Chartwell Investment Partners LLC, Vanguard Group Inc. and Goldman Sachs Group Inc.. Company insiders that have bought G1 THERAPEUTICS stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 THERAPEUTICS.
How do I buy G1 THERAPEUTICS stock?
Shares of G1 THERAPEUTICS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 THERAPEUTICS's stock price today?
One share of G1 THERAPEUTICS stock can currently be purchased for approximately $24.73.
MarketBeat Community Rating for G1 THERAPEUTICS (NASDAQ GTHX)MarketBeat's community ratings are surveys of what our community members think about G1 THERAPEUTICS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for G1 THERAPEUTICS (NASDAQ:GTHX)Earnings History by Quarter for G1 THERAPEUTICS (NASDAQ GTHX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 8/9/2017 | 6/30/2017 | ($0.61) | ($1.09) | | | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for G1 THERAPEUTICS (NASDAQ:GTHX)2017 EPS Consensus Estimate: ($1.19)
2018 EPS Consensus Estimate: ($2.27)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q3 2017 | 1 | ($0.58) | ($0.58) | ($0.58) |
| Q4 2017 | 1 | ($0.61) | ($0.61) | ($0.61) |
| Q1 2018 | 1 | ($0.52) | ($0.52) | ($0.52) |
| Q2 2018 | 1 | ($0.55) | ($0.55) | ($0.55) |
| Q3 2018 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q4 2018 | 1 | ($0.61) | ($0.61) | ($0.61) |
(Data provided by Zacks Investment Research)
Dividend History for G1 THERAPEUTICS (NASDAQ:GTHX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for G1 THERAPEUTICS (NASDAQ:GTHX)Institutional Ownership Percentage: 35.10%
Insider Trades by Quarter for G1 THERAPEUTICS (NASDAQ:GTHX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Clay Thorp | Major Shareholder | Buy | 133,333 | $15.00 | $1,999,995.00 | |
| 5/22/2017 | Fredric N Eshelman | Director | Buy | 300,000 | $15.00 | $4,500,000.00 | |
| 5/22/2017 | Ra Capital Healthcare Fund Lp | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for G1 THERAPEUTICS (NASDAQ:GTHX)
Latest Headlines for G1 THERAPEUTICS (NASDAQ:GTHX)
| Source: |
|
| Date | Headline |
|---|
 | Why Hatteras Venture Partners brought on Andrew Witty
www.bizjournals.com - September 20 at 5:22 AM |
 | G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
finance.yahoo.com - September 18 at 6:48 PM |
 | Analysts Set $29.67 Target Price for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - September 11 at 4:42 AM |
 | SRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR
www.nasdaq.com - September 7 at 5:19 AM |
| G1 THERAPEUTICS (GTHX) Given $29.67 Consensus Target Price by Brokerages
www.americanbankingnews.com - September 4 at 6:44 PM |
| G1 THERAPEUTICS (GTHX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - September 1 at 2:32 PM |
| NCBiotech portfolio companies raise $128M in Q4
www.bizjournals.com - August 26 at 6:31 PM |
 | Gainers & Losers Of Aug.21: CHRS, GTHX, OTIC, APEN, PETS...
www.finanznachrichten.de - August 21 at 11:39 PM |
| Brokerages Anticipate G1 THERAPEUTICS (GTHX) to Post ($0.56) Earnings Per Share
www.americanbankingnews.com - August 17 at 12:36 PM |
| Q3 2017 Earnings Estimate for G1 THERAPEUTICS Issued By Wedbush (GTHX)
www.americanbankingnews.com - August 14 at 2:52 AM |
| Head-To-Head Comparison: G1 THERAPEUTICS (GTHX) vs. AVEO Pharmaceuticals (AVEO)
www.americanbankingnews.com - August 11 at 4:58 PM |
| G1 THERAPEUTICS (NASDAQ:GTHX) to Post Q1 2018 Earnings of ($0.52) Per Share, Wedbush Forecasts
www.americanbankingnews.com - August 11 at 2:14 PM |
| G1 THERAPEUTICS (GTHX) Announces Quarterly Earnings Results, Misses Estimates By $0.48 EPS
www.americanbankingnews.com - August 10 at 9:52 PM |
| G1 THERAPEUTICS (GTHX) Given "Buy" Rating at Cowen and Company
www.americanbankingnews.com - August 9 at 9:10 PM |
| G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 9 at 7:29 PM |
| G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 7:01 PM |
| G1 Therapeutics Makes Key Appointments to Management Team
finance.yahoo.com - August 3 at 7:16 PM |
| Analysts Set $29.33 Price Target for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - August 2 at 8:30 AM |
| G1 Therapeutics, Inc. (Nasdaq: GTHX) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - August 1 at 7:51 PM |
| G1 THERAPEUTICS (GTHX) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - July 30 at 6:22 PM |
| G1 Therapeutics to Ring Nasdaq Stock Market Closing Bell on Wednesday, August 2, 2017
finance.yahoo.com - July 27 at 7:51 PM |
| Zacks: G1 THERAPEUTICS (NASDAQ:GTHX) Receives Average Rating of "" from Brokerages
www.americanbankingnews.com - July 18 at 5:02 PM |
| G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors
finance.yahoo.com - July 14 at 2:46 AM |
| Zacks: Analysts Anticipate G1 THERAPEUTICS (GTHX) Will Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - July 6 at 2:30 PM |
| Brokerages Anticipate G1 THERAPEUTICS (GTHX) to Announce ($0.82) EPS
www.americanbankingnews.com - July 3 at 10:40 AM |
| With IPO under its belt, important milestones on the horizon for G1 Therapeutics
finance.yahoo.com - June 28 at 6:54 PM |
| G1 THERAPEUTICS's Quiet Period To End on June 26th (NASDAQ:GTHX)
www.americanbankingnews.com - June 19 at 8:12 AM |
| Zacks: G1 THERAPEUTICS (GTHX) Given $29.75 Consensus Price Target by Brokerages
www.americanbankingnews.com - June 14 at 11:08 AM |
| G1 THERAPEUTICS (GTHX) Coverage Initiated at Needham & Company LLC
www.americanbankingnews.com - June 12 at 3:38 PM |
| G1 THERAPEUTICS (GTHX) Research Coverage Started at Wedbush
www.americanbankingnews.com - June 12 at 9:38 AM |
| G1 THERAPEUTICS (GTHX) Research Coverage Started at Cowen and Company
www.americanbankingnews.com - June 12 at 9:16 AM |
| G1 THERAPEUTICS (GTHX) Now Covered by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - June 12 at 9:16 AM |
 | JPMorgan Starts G1 Therapeutics (GTHX) at Overweight
www.streetinsider.com - June 12 at 3:46 AM |
| Retail Investors: Your IPOs Are Here
finance.yahoo.com - June 9 at 6:00 PM |
| G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 30 at 10:56 AM |
| G1 Therapeutics, Inc. (GTHX)
finance.yahoo.com - May 27 at 5:55 PM |
| IPOs This Week: Software Maker Appian Plus 3 More Hopefuls
finance.yahoo.com - May 25 at 10:55 AM |
| G1 Therapeutics Announces Closing of Initial Public Offering
finance.yahoo.com - May 25 at 10:55 AM |
| G1 Therapeutics Inc (GTHX) Major Shareholder Buys $1,999,995.00 in Stock
www.americanbankingnews.com - May 24 at 10:14 PM |
| Ra Capital Healthcare Fund Lp Acquires 400,000 Shares of G1 Therapeutics Inc (GTHX) Stock
www.americanbankingnews.com - May 24 at 10:14 PM |
| G1 Therapeutics Inc (GTHX) Director Fredric N. Eshelman Purchases 300,000 Shares
www.americanbankingnews.com - May 24 at 10:14 PM |
| G1 Therapeutics (GTHX) Plans to Raise $101 Million in May 17th IPO
www.americanbankingnews.com - May 9 at 10:20 AM |
G1 THERAPEUTICS (GTHX) Chart for Monday, September, 25, 2017
